9. UBRICA ONE BIOMEDICAL INDUSTRIAL CITY

We propose to implement Ubrica One Biomedical Industrial City in Kenya (“Ubrica One”). We will build Ubrica One on multiple disparate land parcels all aggregating to approximately 4,000-acres. The complete project will be multiple master-planned biomedical industrial parks with specialty hospitals fashioned as academic medical centers (“AMCs”), research facilities, residential areas, and specialized industrial zones.

9.1. STRATEGY

Ubrica one will host a Children & Women’s AMC, a Heart & Lungs AMC, a Neuroscience & Rehabilitation AMC, a Trauma & Orthopedic AMC, an Eye & Ear AMC, a Cancer Hospital & Hospice Care AMC,  a Tropical & Infectious Diseases AMC, a Renal & Urologic AMC, a Gastro-Intestinal Diseases AMC.

9.1.1.         Vision

Our vision is to create places that will be lead centers of excellence in global health in:

  • discovery, development, and commercialization of cutting edge technologies in biomedicine
  • world class services in health promotion, disease detection, disease prevention, and disease treatment.

9.1.2. Mission

Our mission is to establish and sustain leadership in:

  • Translational research in human biology, human physiology and human medicine
  • Nano-science, biotechnology, molecular biology and human genetics
  • Clinical medicine
  • Organization of systems of delivery of care
  • Information systems for health

9.1.3. Theoretical Underpinning

Our project is underpinned by the theory of knowledge conversion continuum that explains that knowledge has to traverse five distinct stages to translate in products that people can use to solve problems of everyday life: EXPLORATION—RESEARCH—PUBLICATION—TRANSLATION—APPLICATION.

9.1.4. Phenomenal Structure

The phenomenal structure of Ubrica One is grounded by four primary functions of a world class academic medical center: RESEARCH—EDUCATION—INNOVATION—PATIENT CARE. We propose to build Ubrica One as an all-inclusive development with multiple land uses to be located on an aggregate of 4,000-acre lot of land in Kenya. Upon completion, Ubrica One will be home to eight ultramodern academic specialty medical centers structured as world class HOSPITALS, centers for advanced science in biomedicine structured for advanced RESEARCH, and centers for biomedical translation and innovation structured for COMMERCIALIZATION and MANUFACTURING

TABLE 2. KEY FEATURES OF THE UBRICA ONE BIOMEDICAL INDUSTRIAL CITY

Structure Function
HOSPITALS Eight ultramodern academic medical centers providing patient care and education.
RESEARCH Centers for advanced biomedical research.
PRODUCT COMMERCIALIZATION and MANUFACTURE Centers for advanced biomedical translation, innovation, and commercialization of knowledge into products and services for home and clinical use, and manufacture of products.

 

The phenomenal structure of the Ubrica One is underpinned by the theory of advanced academic medical center that is built on the principle of integration to collocate the functions of advanced research in science technology and medicine [RESEARCH], world class medical and science education [TEACHING], translation of research knowledge products into commercial products for everyday use at home and in the clinical environments [INNOVATION], and delivery of care of the highest quality possible [PATIENT CARE] (Figure 8).

img class=”alignnone wp-image-419 size-full” src=”https://ubricoin.ubrica.com/wp-content/uploads/2018/06/bmic.jpg” sizes=”(max-width: 1347px) 100vw, 1347px” srcset=”https://ubricoin.ubrica.com/wp-content/uploads/2018/06/bmic.jpg 1347w, https://ubricoin.ubrica.com/wp-content/uploads/2018/06/bmic-560×146.jpg 560w, https://ubricoin.ubrica.com/wp-content/uploads/2018/06/bmic-300×78.jpg 300w, https://ubricoin.ubrica.com/wp-content/uploads/2018/06/bmic-768×200.jpg 768w, https://ubricoin.ubrica.com/wp-content/uploads/2018/06/bmic-1024×266.jpg 1024w, https://ubricoin.ubrica.com/wp-content/uploads/2018/06/bmic-1200×312.jpg 1200w” alt=”” width=”1347″ height=”350″ />FIGURE 8. PHENOMENAL STRUCTURE OF UBRICA ONE DEPICTING FUNCTIONAL KINSHIP OF AN ADVANCED ACADEMIC MEDICAL CENTER THAT INTEGRATES RESEARCH, TEACHING AND INNOVATION WITH PATIENT CARE.

 

This proposal contains a brief description of the project, starting with the explanation of the background of the problem that the project is meant to solve. In addition, the proposal explains the purpose of Ubrica, the general approach to implementation, and the significance of implementation Ubrica One.
9.2. STATEMENT OF INTENT

Our intent is to create in Kenya, centers of excellence for (a) discovery, development and commercialization of cutting edge technologies in biomedicine, and (b) world class health care services in health promotion, disease prevention, and treatment. Two major and closely interrelated problems motivate our intent:

  • The severe inadequate infrastructure for global health. Health services in many countries of the world are unsafe, of low quality, and inaccessible to majority of the people.  People, afraid to use health services locally, seek medical care in other countries. Indeed, healthcare consumers would be willing to pay more for better care that is of high value, of efficient supply of drugs, of better technical quality, of well-maintained health facilities, and of short wait times. The specific problem is that an entity that can produce comprehensive world-class medical service is lacking.  Ubrica One will be home to five ultramodern academic specialty medical centers structured as world-class hospitals to deliver care of the highest quality possible.
  • The absence of health services and biomedical innovative research and development (R&D) capability. Ubrica One is poised to create a world-class research facilities attached to the world-class hospitals. The research facilities will serve as centers for research excellence in Kenya. The centers will produce the best-in class researchers in health, medicine, and basic sciences. The research facilities will also serve as technology transfer organizations that will manage intellectual property, licensing, and commercialization of products of research, and industrial development to meet health needs of people.

9.3. BACKGROUND OF THE PROBLEM

In this section we present the background of the problem addressed in this proposal from the framework of knowledge conversion. The section underpins knowledge conversion as the centerpiece of national development, emphasizing the central importance of comprehending knowledge conversion to comprehend development.
9.3.1. Theoretical Underpinning: National Development a Function of Knowledge Conversion

Knowledge conversion is the work of discovering knowledge residing in the local environments and mastering the discovered knowledge to create products and services that people and organizations can use to advance themselves and to defend themselves from enemies. Knowledge converts in five steps starting from exploration, going to research, then to publication, then to translation and finally to application of knowledge (Figure 9).

FIGURE 9. USTAWI STAGES OF KNOWLEDGE CONVERSION CONTINUUM

Note. From, Macharia Waruingi (2010). Knowledge conversion by open innovation. Ustawi the knowledge conversion organization. Minnetonka, MN: Ustawi. (Used with permission of author.)

 

Human development depends on capability of people residing in that nation, to muster all the five stages of knowledge conversion in all fields of knowledge. A developed nation in biomedicine, for example, is the one that has built a full-scale capability for exploratory work in biomedicine, biomedical research, publication and dissemination of biomedical knowledge, translation of published biomedical knowledge into products such as pharmaceuticals and medical devices and systems for delivery of health care services, and application of biomedical knowledge in health promotion, disease prevention, cure of disease, and education of present and future generations of care providers.  Table 4 depicts the steps in the knowledge conversion continuum in biomedicine.

TABLE 3. STAGES OF THE KNOWLEDGE CONVERSION CONTINUUM, AND PRODUCTS ASSOCIATED TO EACH STAGE

  Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Process Exploration Research Publication Translation Application
Product Discovery of facts, theories, and propositions, Verification of facts, theories, and propositions JournalsThesis

Text books

Popular books

Art

Intellectual capital management, patents PharmaceuticalsMedical devices

Health delivery systems

Education systems

 

Typically, underdeveloped nations lack the will to develop capability for exploration, research, and translation of knowledge. Because they lack the will to develop these capabilities, they rely for their existence, on application of products and services created from knowledge discovered in other countries. They rely on foreign facts, theories and propositions to implement their work programs in their nations. Facts, theories and propositions from foreign sources do not have working capacity in local situations because they do not fit. Because of this problem, nations that rely on theories developed from knowledge products generated for a foreign nation remain underdeveloped and subservient to the nations from where the theories originated.
9.3.2. Relevance

For example, theories about approach to diseases developed from knowledge collected in Boston, Massachusetts in the United States is of little help to a clinician in Nyeri County dealing with medical conditions local to Nyeri County  Hospital in Kenya; much less in a health center in Mukurweini, or Othaya in Kenya. Geography, culture, climate and other local forces have it that diseases that occur in Nyeri are different from the diseases that occur in Boston. Furthermore, the local environments (culture, diet, nutrition, climate, geography, economy) affect the human physiology in such manner that the physiology adapts to local conditions. Indeed, the local environment modifies human genetic expression, which in turn modifies the human physiology for adaptation to needs of the local environment.
9.3.3. Relevance Paradox

Humans who live in hot climates are comfortable in high temperatures and do not tolerate the cold climates without a period of acclimatization. Similarly, humans who live in the lowlands with high oxygen tension do not tolerate low oxygen-tension highlands without a period of acclimatization. This physiological adaptation of individuals means that the human body tolerates medications differently according to local environment. Rather, factors in local environment determine the effectiveness of a medical treatment given to an individual. As such, medicines developed with knowledge gathered from Boston dwellers, may have lower effectiveness on Nyeri dwellers. Thus, use of knowledge from Boston to solve problems plaguing people in Nyeri leads to incomplete solutions, with attendant negative consequences.
9.3.4. Exploration and Discovery

Theories and propositions about how do help people deal with medical problems in Nyeri must come from the work of discovery of such knowledge in Nyeri, and not Boston. Theories and propositions about health and disease in Nyeri must be verified through formal research about health and disease in Nyeri.
9.3.5. Intellectual Property Protection

The discovered theories, propositions, and their verifications must be protected with appropriate regulations and patents to safeguard loss of intellectual property. Unprotected intellectual property is open to exploitation by outsiders leading to tremendous loss.
9.3.6. Publication

After appropriate protection, the discovered theories, propositions, and their verifications must be published in journals, books, thesis, monographs for dissemination to schools, universities, government organizations, non-governmental organizations, business organizations, and indeed to all interested individuals. The published knowledge is then available for creation of new products and services that have fit and working capacity in the local environment. Local companies can use the translated knowledge to create medicines, medical devices, health delivery systems, medical services systems, etc.
9.3.7. Application

The glaring absence of medical manufacturing in African countries, and the extremely poor quality of medical services is the product of lack of attention to exploration, research, publication and translation of local knowledge. A country that has no local knowledge resembles a human being whose higher center of the brain is amputated.
9.3.8. Knowledge Conversion in Biomedicine for Global Health

Developing countries lag behind in knowledge conversion in biomedicine. Many governments of developing countries allocate no investments on exploration of knowledge that would lead to discovery of bio-medical facts, theories and propositions. Furthermore, governments of developing countries invest very little in research that would lead to verification of facts, theories and propositions. They do not invest in discovery and verification for the benefit of the citizens of their nations. To overcome this problem, we must discover new ways of funding knowledge conversion in biomedicine for global health using blockchain.
9.3.9. Private Sector and Knowledge Conversion in Biomedicine in the World

Private health care sector has historically played an important role in health services delivery in developing countries. The absence of a well-organized health insurance system and ambivalence in health care financing, however, limit the growth of the private health care. In recent years, several developing countries have rapidly re-emerged from grinding poverty, and business is springing back. The national leadership is supportive of the private health care enterprise, encouraging private investment in health care and medical facilities. The general problem is that health systems in developing countries, suffering long-term neglect and lack of investment, is indeed inadequate, with high rate of infection in hospitals and limited medical equipment.

Investment in world-class Ubrica One Biomedical Industrial City will help to overcome the problem of global health. Specifically, Ubrica One will be the beacon of hope for biomedical discovery and a source of excellence in bio-scientific publications. In addition, Ubrica One will lead to a new horizon of translational medicine, medical devices and pharmaceutical manufacturing for global health.
9.4. BMIC 3 BILLION UBNs

We will sell 3 billion UBNs to fund biomedical industrial city. This sale will occur in 2024 at US $10 per coin. The fund raised will be used for design, development, construction and management of BMIC. We will issue coins to facilitate construction and post construction management of biomedical industrial city, to function as epicenter for discovery and development of medical innovations for global health.
9.4.1. Reward System

Holders of Ubricoin will receive discounted services at the biomedical industrial Center. The discounted services will include: healthcare services, hospitality and tourism. The users of BMIC will receive loyalty point.
9.4.2. Reuse of points

The loyalty points will be used to assess services in the Ubrica ecosystem such as shopping on Soko Janja and receiving services in URCCs. The points will also be used in the pooled smart contract.

The 3 billion coins will be issued in four phases each phase raising funds to support different segments of this project.

 

Biomedical Industrial City Timeline Tokens@$10/token Phases  Uses
April 1, 2024 200M Private Sale

 

Design ·         Desktop and field research·         Doctors and other professionals

·         User research

June 1, 2024 300M Pre-sale Development ·         Physical planning, geotechnical studies, suitability analysis, Architecture, Engineering, Economic planners, Construction planning, Security, Information technology.
August 1, 2024 1.5B Crowdsale Construction ·         Land purchase and entitlement·         Government
October 1, 2024 1B Initial Token Offering Management ·         Mortgages·         Incentives

·         Customer satisfaction

·         Excellence in education, clinical practice and performance in all fields

9.4.3. Phase 1. Private sale

We will issue 200 million UBNs to facilitate the design of the BMIC, setting out the strategy and deciding on the best model for implementation. We require a lot of desktop and field research to understand the BMIC scope. This will be done by a team of professionals.
9.4.4. Phase 2. Presale

In this stage we will issue 300 million UBNs. This will be used for the development of BMIC. We will identify and hire architects, engineers and planners who will be responsible for developing the project scope and planning the implementation of the BMIC.

These funds will be used to do feasibility studies which will include Physical planning, geotechnical studies, suitability analysis, Architecture, Engineering, Economic planners, Construction planning, Security, Information technology.
9.4.5. Phase 3. Crowdsale

We will issue 1.5 billion UBNs to facilitate the construction of the BMIC. We intend to construct BMIC in Kenya. These funds will be used to purchase land, entitlement and the construction material for this project. The raised funds will also be used to do monitoring and evaluation of the project.
9.4.6.Phase 4. Initial Token Offering

We will issue 1 billion UBNs to support management of the BMIC. We will use the funds to create a mortgage program to facilitate ownership of medical and scientific real estate. We will also create a reserve fund to support operation of innovation hubs within the BMIC, until breakeven. Operations of an innovation within the BMIC will be responsible for generating high quality research, idea innovation, translation/commercialization of knowledge into products and services that help solve local problems. The BMIC will bridge the university with the industry and with the local community.

To stimulate new innovation we will create a bounty programs to reward individuals or groups with new scientific ideas that will help provide solutions to our vexing problems. We will issue tokens to people who will

  • do original research,
  • publish the results of their original research,
  • present the results of their research in scientific conferences locally and internationally,
  • translate their research knowledge into commercial prototypes, and
  • commercialize their prototypes into products of everyday use.

Leave a Reply

Your email address will not be published. Required fields are marked *